Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Depreciation & Amortization (CF) (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $356034.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 48.91% year-over-year to $356034.0, compared with a TTM value of $1.5 million through Sep 2025, down 49.25%, and an annual FY2024 reading of $2.6 million, down 4.92% over the prior year.
  • Depreciation & Amortization (CF) was $356034.0 for Q3 2025 at China Pharma Holdings, up from $320863.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $976457.0 in Q3 2021 and bottomed at $320863.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $640330.6, with a median of $694842.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 45.03% in 2021, then tumbled 56.6% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $710716.0 in 2021, then fell by 10.03% to $639425.0 in 2022, then rose by 8.82% to $695835.0 in 2023, then plummeted by 35.61% to $448073.0 in 2024, then dropped by 20.54% to $356034.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CPHI at $356034.0 in Q3 2025, $320863.0 in Q2 2025, and $329313.0 in Q1 2025.